Compare Citius Pharmaceuticals Inc (CTXR) vs iShares International Treasury Bond ETF (IGOV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs iShares International Treasury Bond ETF — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while iShares International Treasury Bond ETF trades at $39.71 (market cap $1.30B). The key difference: iShares International Treasury Bond ETF is far larger — about 95.4× Citius Pharmaceuticals Inc's market cap, and iShares International Treasury Bond ETF is more actively traded (693,740 versus 132,438). Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and iShares International Treasury Bond ETF for 92 Days on average.
| CTXR | IGOV | |
|---|---|---|
Market Cap | $13.62M | $1.30B |
Volume | 132,438 | 693,740 |
Sector | Health | Fixed Income |
52-Week High | $1.82 | $42.99 |
52-Week Low | $0.48 | $39.65 |
Typical Hold Time | 17 Days | 92 Days |
Enterprise Value | $3.79M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.4994, down 1.73% with a bearish technical signal despite oscillators showing oversold conditions. The company reported $7.1M revenue for the first nine months of 2026 from LYMPHIR commercial sales, but continues to post significant losses with a -651.27% net income margin. Recent news highlights strong commercial momentum for LYMPHIR with 44 institutions ordering the treatment since launch.
The stock presents a high-risk opportunity with analyst consensus strongly bullish (83% buy ratings, $5 price target) but fundamental challenges persist. Key risks include ongoing cash burn and execution of commercial strategy, while potential upside depends on successful LYMPHIR adoption and path to profitability.
IGOV trades at $39.74 with minimal daily movement (+0.1%). Technical indicators show a bearish bias with moving averages signaling selling pressure, though oscillators remain neutral. The stock faces resistance at $40 across multiple levels, indicating consolidation. Financial ratios are unavailable in current data, limiting fundamental assessment of valuation and profitability metrics.
The bearish technical setup suggests near-term caution, though neutral RSI readings indicate potential stabilization. Rising bond yields create macroeconomic headwinds for equities, but specific company fundamentals require updated SEC filings for proper evaluation. Investment appeal hinges on upcoming earnings clarity amid broader market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About iShares International Treasury Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index and will invest at least 90% of its assets in fixed income securities included in the underlying index. The underlying index measures the performance of fixed-rate, local currency, investment-grade, sovereign bonds from certain developed markets. The fund is non-diversified.
Read more on IGOV →
